{"id":"https://openalex.org/W2987654547","doi":"https://doi.org/10.1002/cam4.2625","title":"Real\u2010world survival of patients with advanced BRAF V600 mutated melanoma treated with front\u2010line BRAF/MEK inhibitors, anti\u2010PD\u20101 antibodies, or nivolumab/ipilimumab","display_name":"Real\u2010world survival of patients with advanced BRAF V600 mutated melanoma treated with front\u2010line BRAF/MEK inhibitors, anti\u2010PD\u20101 antibodies, or nivolumab/ipilimumab","publication_year":2019,"publication_date":"2019-11-02","ids":{"openalex":"https://openalex.org/W2987654547","doi":"https://doi.org/10.1002/cam4.2625","mag":"2987654547","pmid":"https://pubmed.ncbi.nlm.nih.gov/31677253","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6912019"},"language":"en","primary_location":{"id":"doi:10.1002/cam4.2625","doi":"https://doi.org/10.1002/cam4.2625","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cam4.2625","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.2625","source":{"id":"https://openalex.org/S2754843627","display_name":"Cancer Medicine","issn_l":"2045-7634","issn":["2045-7634"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Medicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.2625","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103227088","display_name":"Justin C. Moser","orcid":"https://orcid.org/0000-0002-4427-9387","observed_orcids":["https://orcid.org/0000-0002-4427-9387"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Justin C. Moser","raw_affiliation_strings":["HonorHealth Research Institute, Scottsdale, AZ, USA"],"raw_orcid":"https://orcid.org/0000-0002-4427-9387","affiliations":[{"raw_affiliation_string":"HonorHealth Research Institute, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210130412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016186409","display_name":"Danli Chen","orcid":"https://orcid.org/0009-0008-3827-1742","observed_orcids":["https://orcid.org/0009-0008-3827-1742","https://orcid.org/0009-0001-9010-7404"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danli Chen","raw_affiliation_strings":["Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062344802","display_name":"Siwen Hu\u2010Lieskovan","orcid":"https://orcid.org/0000-0001-5836-4710","observed_orcids":["https://orcid.org/0000-0001-5836-4710"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Siwen Hu\u2010Lieskovan","raw_affiliation_strings":["Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073549408","display_name":"Kenneth F. Grossmann","orcid":"https://orcid.org/0000-0002-8523-7407","observed_orcids":["https://orcid.org/0000-0002-8523-7407"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth F. Grossmann","raw_affiliation_strings":["Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059049062","display_name":"Shiven B. Patel","orcid":"https://orcid.org/0000-0002-7582-646X","observed_orcids":["https://orcid.org/0000-0002-7582-646X"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shiven Patel","raw_affiliation_strings":["Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057316081","display_name":"Sarah Violet Colonna","orcid":"https://orcid.org/0000-0002-9026-6990","observed_orcids":["https://orcid.org/0000-0002-9026-6990"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah V. Colonna","raw_affiliation_strings":["Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113486332","display_name":"Jian Ying","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jian Ying","raw_affiliation_strings":["Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002699089","display_name":"John Robert Hyngstrom","orcid":"https://orcid.org/0000-0002-4833-3838","observed_orcids":["https://orcid.org/0000-0002-4833-3838"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John R. Hyngstrom","raw_affiliation_strings":["Surgical Oncology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Surgical Oncology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5103227088"],"corresponding_institution_ids":["https://openalex.org/I4210130412"],"apc_list":{"value":2750,"currency":"USD","value_usd":2750},"apc_paid":{"value":2750,"currency":"USD","value_usd":2750},"fwci":3.3608,"has_fulltext":true,"cited_by_count":59,"citation_normalized_percentile":{"value":0.94155627,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"8","issue":"18","first_page":"7637","last_page":"7643"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.016499999910593033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-v600-mutant-melanoma","display_name":"BRAF V600-mutant melanoma","score":0.9409999847412109},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8999999761581421},{"id":"https://openalex.org/keywords/braf-mek-inhibitors","display_name":"BRAF/MEK inhibitors","score":0.9169999957084656},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9169999957084656},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9570000171661377},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.765999972820282},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6349999904632568},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.972000002861023},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.7440000176429749}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8933025002479553},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8161290287971497},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8100814819335938},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5854523181915283},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.584969162940979},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5727143883705139},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5451213717460632},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5321817398071289},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.45248064398765564},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.41327109932899475},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36426639556884766},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2739816904067993},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2631615996360779},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.07011935114860535},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06666526198387146},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000483","descriptor_name":"Alleles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019943","descriptor_name":"Amino Acid Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1002/cam4.2625","doi":"https://doi.org/10.1002/cam4.2625","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cam4.2625","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.2625","source":{"id":"https://openalex.org/S2754843627","display_name":"Cancer Medicine","issn_l":"2045-7634","issn":["2045-7634"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Medicine","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5877128","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6912019","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6912019","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6912019","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Med","raw_type":"Text"},{"id":"pmid:31677253","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31677253","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer medicine","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:52b6fa49a3e44388aa94c0a04848fd13","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/52b6fa49a3e44388aa94c0a04848fd13","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer Medicine, Vol 8, Iss 18, Pp 7637-7643 (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/cam4.2625","doi":"https://doi.org/10.1002/cam4.2625","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cam4.2625","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.2625","source":{"id":"https://openalex.org/S2754843627","display_name":"Cancer Medicine","issn_l":"2045-7634","issn":["2045-7634"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2987654547.pdf","grobid_xml":"https://content.openalex.org/works/W2987654547.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1819015028","https://openalex.org/W2052005627","https://openalex.org/W2096387850","https://openalex.org/W2121545342","https://openalex.org/W2416791964","https://openalex.org/W2499375061","https://openalex.org/W2549612601","https://openalex.org/W2611270905","https://openalex.org/W2620651944","https://openalex.org/W2753432434","https://openalex.org/W2758315173","https://openalex.org/W2761314488","https://openalex.org/W2793817570","https://openalex.org/W2804210712","https://openalex.org/W2888298425","https://openalex.org/W2896600825","https://openalex.org/W2917811217","https://openalex.org/W2951285627","https://openalex.org/W3043703771"],"related_works":["https://openalex.org/W4200046162","https://openalex.org/W4388723026","https://openalex.org/W3028730736","https://openalex.org/W3094969222","https://openalex.org/W3094502178","https://openalex.org/W4284669148","https://openalex.org/W4385851408","https://openalex.org/W3122239502","https://openalex.org/W4415354669","https://openalex.org/W2917811217"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1],"optimal":[2],"treatment":[3,214],"sequence":[4],"for":[5,186,199],"patients":[6,51,152,187,200,236],"with":[7,28,52,58,67,153,158,189,202,215,221,237,243,255],"advanced":[8,53,68,154,238],"BRAF":[9,54,69,239],"V600":[10],"mutant":[11,55,70,240],"melanoma":[12,56,71,241],"is":[13],"unknown.":[14],"BRAF/MEK":[15],"inhibition":[16,27],"(BRAF/MEKi),":[17],"single":[18],"agent":[19],"anti-PD-1":[20],"(aPD-1)":[21],"antibodies":[22],"and":[23,30,93,107,111,133,149,156,209,217],"combination":[24],"immune":[25],"checkpoint":[26],"nivolumab":[29],"ipilimumab":[31],"(niv/ipi)":[32],"are":[33],"all":[34],"approved;":[35],"however,":[36],"they":[37],"have":[38],"not":[39,193],"been":[40],"prospectively":[41],"compared.":[42],"Therefore,":[43],"we":[44],"sought":[45],"to":[46,118,252],"compare":[47],"overall":[48,183],"survival":[49,184,224,250],"of":[50,122,179],"treated":[57,157,188,201,242,254],"either":[59],"front-line":[60,81,123,159,190,244,256],"BRAF/MEKi,":[61,75],"aPD-1,":[62],"or":[63,77,127,131,142,168,204,246],"niv/ipi.":[64],"METHODS:":[65],"Patients":[66],"who":[72],"had":[73,248],"received":[74],"niv/ipi,":[76],"aPD-1":[78,160,203,247],"in":[79,227],"the":[80,120],"setting":[82],"were":[83,116,173,219],"identified":[84],"from":[85,97],"a":[86,176],"nationwide":[87],"database":[88],"comprising":[89],"de-identified":[90],"patient-level":[91],"structured":[92],"unstructured":[94],"data":[95],"derived":[96],"electronic":[98],"health":[99],"records.":[100],"Survival":[101],"was":[102,192,206],"compared":[103,251],"using":[104],"Kaplan-Meier":[105],"curves":[106],"log-rank":[108],"analysis.":[109],"Univariate":[110],"multivariate":[112,228],"Cox":[113],"regression":[114],"models":[115],"used":[117],"measure":[119],"effect":[121],"treatment,":[124],"age":[125],"(>64":[126],"not),":[128,132],"LDH":[129],"(elevated":[130],"Eastern":[134],"Cooperative":[135],"Oncology":[136],"Group":[137],"(ECOG)":[138],"performance":[139],"status":[140],"(>1":[141],"not)":[143],"on":[144],"survival.":[145],"RESULTS:":[146],"Five":[147],"hundred":[148],"sixty":[150],"seven":[151],"disease":[155],"(n":[161,165,170],"=":[162,166,171],"162),":[163],"BRAF/MEKi":[164,205,226],"297)":[167],"niv/ipi":[169,191,218,245],"108)":[172],"identified.":[174],"With":[175],"median":[177,182,197],"follow-up":[178],"22.4":[180],"months,":[181,211],"(OS)":[185],"reached":[194],"(NR)":[195],"while":[196],"OS":[198],"39.5":[207],"months":[208],"13.2":[210],"respectively.":[212],"Front-line":[213],"PD-1":[216],"associated":[220],"statistically":[222],"longer":[223,249],"than":[225],"analyses.":[229],"CONCLUSIONS:":[230],"In":[231],"our":[232],"real-world":[233],"retrospective":[234],"analysis,":[235],"those":[253],"BRAF/MEKi.":[257]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":13}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}